CorMedix   Report issue

For profit Phase 3
Founded: Bridgewater NJ United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2010
NCT01146925
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (4)

citric acid (1 trial)

deferiprone (ferriprox) (2 trials)

heparin (liquaemin) (1 trial)

tauroline (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Catheter-Related Infections (Phase 3)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4